Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Heparanase promotes the spontaneous metastasis of myeloma cells to bone.

Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, Kelly T, Sanderson RD.

Blood. 2005 Feb 1;105(3):1303-9. Epub 2004 Oct 7.

2.

Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.

Sanderson RD, Yang Y, Suva LJ, Kelly T.

Matrix Biol. 2004 Oct;23(6):341-52. Review.

PMID:
15533755
3.

Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis.

Ilan N, Elkin M, Vlodavsky I.

Int J Biochem Cell Biol. 2006;38(12):2018-39. Epub 2006 Jul 6. Review.

PMID:
16901744
4.

Heparanase, heparin and the coagulation system in cancer progression.

Vlodavsky I, Ilan N, Nadir Y, Brenner B, Katz BZ, Naggi A, Torri G, Casu B, Sasisekharan R.

Thromb Res. 2007;120 Suppl 2:S112-20. Review. Erratum in: Thromb Res. 2008;123(1):187-90.

PMID:
18023704
5.

Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis.

Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I.

FEBS J. 2010 Oct;277(19):3890-903. doi: 10.1111/j.1742-4658.2010.07799.x. Epub 2010 Aug 31. Review.

6.

Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate.

Vlodavsky I, Ilan N, Naggi A, Casu B.

Curr Pharm Des. 2007;13(20):2057-73. Review.

PMID:
17627539
7.

Development of heparanase inhibitors for anti-cancer therapy.

Miao HQ, Liu H, Navarro E, Kussie P, Zhu Z.

Curr Med Chem. 2006;13(18):2101-11. Review.

PMID:
16918340
8.

Heparanase: one molecule with multiple functions in cancer progression.

Vlodavsky I, Elkin M, Abboud-Jarrous G, Levi-Adam F, Fuks L, Shafat I, Ilan N.

Connect Tissue Res. 2008;49(3):207-10. doi: 10.1080/03008200802143281. Review.

PMID:
18661344
9.

Genomics and proteomics of bone cancer.

Marguiles AG, Klimberg VS, Bhattacharrya S, Gaddy D, Suva LJ.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6217s-6221s. Review.

10.

Heparanase, tissue factor, and cancer.

Nadir Y, Vlodavsky I, Brenner B.

Semin Thromb Hemost. 2008 Mar;34(2):187-94. doi: 10.1055/s-2008-1079259. Review.

PMID:
18645924
11.

The role of heparanase in gastrointestinal cancer (Review).

Naomoto Y, Takaoka M, Okawa T, Nobuhisa T, Gunduz M, Tanaka N.

Oncol Rep. 2005 Jul;14(1):3-8. Review.

PMID:
15944760
12.

[An autopsy case of IgA (kappa) multiple myeloma characterized with pleural fluid and multiple extramedullary tumor formation].

Sugawara M, Sugaya N, Wakabayashi Y, Hirose S.

Rinsho Ketsueki. 1987 Dec;28(12):2133-9. Review. Japanese. No abstract available.

PMID:
3133508
13.

Tumor bone diseases: molecular mechanisms and opportunities for novel treatments.

Susa M, Glatt M, Teti A.

Curr Med Chem Anticancer Agents. 2001 Nov;1(3):313-29. Review.

PMID:
12678761
14.

Heparanase: a universal immunotherapeutic target in human cancers.

Zhang YF, Tang XD, Gao JH, Fang DC, Yang SM.

Drug Discov Today. 2011 May;16(9-10):412-7. doi: 10.1016/j.drudis.2011.02.015. Epub 2011 Mar 1. Review.

PMID:
21376137
15.

[Cell proliferation and cell death in disseminated tumor cells].

Méhes G, Ladenstein R, Gadner H, Ambros PF.

Acta Med Austriaca Suppl. 2002;59:62-4. Review. German.

PMID:
12506763
16.

[Heparanase and neoplasm metastasis].

Zhu Z, Yin Z, Wu M.

Zhonghua Bing Li Xue Za Zhi. 2000 Aug;29(4):300-2. Review. Chinese. No abstract available.

PMID:
12790110
17.

Lung cancer, malignant melanoma, multiple myeloma.

Kemp C.

Am J Hosp Palliat Care. 1999 May-Jun;16(3):545-53. Review.

PMID:
10661062

Supplemental Content

Support Center